The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-10-09
DOI
10.3389/fimmu.2018.02100
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models
- (2017) Shujin Cui MEDICAL SCIENCE MONITOR
- Immune Checkpoint Therapy in Renal Cell Carcinoma
- (2016) Chung-Han Lee et al. CANCER JOURNAL
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
- (2016) Jake S. O’Donnell et al. Genome Medicine
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Immuno-oncology combinations: raising the tail of the survival curve
- (2016) Samuel J. Harris et al. Cancer Biology & Medicine
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
- (2016) Mari Mino-Kenudson et al. Cancer Biology & Medicine
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
- (2016) Maarten Swart et al. Frontiers in Oncology
- Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
- (2015) Jennifer A. Wargo et al. SEMINARS IN ONCOLOGY
- Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
- (2015) Kelly Kersten et al. Frontiers in Immunology
- Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
- (2015) Daniel Shin et al. Journal for ImmunoTherapy of Cancer
- Establishment of and Comparison between Orthotopic Xenograft and Subcutaneous Xenograft Models of Gallbladder Carcinoma
- (2014) Qiang Du et al. Asian Pacific Journal of Cancer Prevention
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2014) S.J. Antonia et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Immunological Variation Between Inbred Laboratory Mouse Strains
- (2011) R. S. Sellers et al. VETERINARY PATHOLOGY
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
- (2010) Rupal Ramakrishnan et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
- (2008) Robbert G. van der Most et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search